From Biomarker Discovery to Signature — Discover What’s New
Join us to see how you can accelerate the pace and precision of your cancer research. Our gold-standard ECL assays provide a fast, reliable path to focused, fully validated panels built for translational studies. This year, we are also unveiling a breakthrough in proteomic discovery: a highly multiplexed immunoassay platform with absolute quantitation that can measure hundreds to thousands of analytes. It’s a new level of clarity for complex biology that bridges the gap between discovery and translation.
For 25 years, researchers worldwide have advanced science using Meso Scale Discovery products. Visit our booth to hear more about our commitment to quality and innovation.
Interested in learning more from us?
Pankaj Oberoi
Executive Vice President of Proteomics Technology, Meso Scale Diagnostics
Hans Layman
Executive Director, Oncology, Meso Scale Diagnostics
David Routenberg
Vice President, Advanced Multiplexing, Meso Scale Diagnostics
Save Your Seat at Our Spotlight Theater
Introducing a Novel Integrated Platform to Accelerate the Path from Biomarker Discovery to Signature
Visit Our Booth
Meet our scientific and technical experts/team at Booth #3443 to discuss your cancer research goals and learn how our technologies support workflows from biomarker discovery through validation.
View Our Posters
Monday, April 20, 2026, 9am – 12pm | Poster Section 44, Board 4
- Poster #2529: High throughput immunoproteomics for cancer biomarker discovery
Tuesday, April 21, 2026, 9am – 12pm | Poster Section 25, Board 20
- Poster #4802: Evaluation of the circulating angiome in cancer: Translational assessment of a 44-plex angiogenesis biomarker panel
Tuesday, April 21, 2026, 9am – 12pm | Poster Section 37, Board 13
- Poster #5099: HPV serology for rapid detection of HPV positive oropharyngeal cancer
Wednesday, April 22, 2026, 9am – 12pm | Poster Section 39, Board 8
- Poster #7684: Absolute quantification of 400 plasma proteins using a novel NGS-based immunoassay: Analytical validation and biomarker discovery in breast cancer
Mini-Symposium
Tuesday, April 21, 2026, 2:30pm – 4:30pm | Ballroom 6 B
Abstract #6750:
Highly multiplexed immunoassays enable discovery of multimarker EV surface signatures as novel biomarkersPresenter: David Routenberg, Vice President, Advanced Multiplexing, Meso Scale Diagnostics
Not attending? Complete the form to request our posters or ask for a meeting with one of the team.
Disclaimers: This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research® (AACR) or its members
Not affiliated with or endorsed by AACR.